Skip to content
Article Rich – Lifestyle
Author:
Tongrui Biomedicine (Shanghai) Co., LTD
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
April 28, 2026